Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Fluoxymesterone, best known by the trade name Halotestin, is a synthetic anabolic-androgenic steroid (AAS) with a unique pharmacological profile: it is one of the most androgenic AAS ever marketed, with limited anabolic activity relative to its strong androgenic effects. The compound was first synthesized in 1956 by Upjohn (later Pharmacia, now Pfizer) and approved by the FDA for human use in 1957. It remains FDA-approved today, though with substantially narrower clinical use than in earlier decades.
Halotestin is one of the few 17α-methylated (orally bioavailable) AAS that retains FDA approval for current human use, primarily for:
- Male hypogonadism (primary and hypogonadotropic): replacement therapy in conditions of testosterone deficiency
- Delayed puberty in adolescent boys
- Palliative treatment of metastatic breast cancer in postmenopausal women (1–5 years postmenopausal with hormone-dependent tumors)
The compound is known in non-medical contexts for pronounced central nervous system effects on aggression and irritability alongside limited muscle mass gain. These effects follow from its high androgen receptor binding and direct CNS activity; the underlying neurobiology is incompletely characterized.
The compound has no injectable form.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Oral tablet (Halotestin / Androxy, not esterified) | ~9.2 hours |
What it does
Main effects
- High androgenic activity: published anabolic-androgenic ratio ~1900:850 actually understates how androgenic-dominant fluoxymesterone is in practical use
- Pronounced CNS effects: aggression and irritability are among the most consistently reported effects; the underlying neurobiology is incompletely characterized
- Acute strength effects: often described as greater than the muscle mass effect would predict
- No water retention: does not aromatize meaningfully
- Orally bioavailable via 17α-methyl modification (also the source of hepatic risk)
- FDA-approved for hypogonadism, delayed puberty, and palliative breast cancer treatment; one of the few continuously-approved 17α-alkylated AAS
What to watch for
Common side effects
- Severe hepatotoxicity via 17α-alkylation: cholestatic jaundice, peliosis hepatis, and hepatocellular carcinoma documented; standard 17α-alkylated steroid concerns apply
- "Halotestin rage": pronounced aggression and irritability widely reported; among the most consistent features; can create direct social, legal, and relationship consequences
- Dramatic lipid changes: significant HDL reduction and LDL elevation
- Profound HPG axis suppression
- Paradoxical estrogenic effects despite no aromatization: gynecomastia has been documented; mechanism debated (likely direct ER activity, similar to oxymetholone); aromatase inhibitors are typically ineffective; gynecomastia warrants evaluation by a qualified healthcare provider
- Severe acne and androgenic skin effects: pronounced given the high androgenic activity
- Aggressive scalp hair loss in genetically predisposed users; 5α-reductase inhibitors have limited effect (reduced 5α-reduction substrate)
- Limited muscle mass gains relative to androgenic effects; users seeking mass often escalate doses inappropriately, encountering aggression and hepatotoxicity without achieving desired mass gains
- Rapid virilization in women, particularly problematic given high androgenic potency
- Connective tissue / strength imbalance risk: strength gains may exceed connective tissue capacity, increasing injury risk during intense training
Key facts
Key facts worth knowing
- Fluoxymesterone is structurally 17α-methyl testosterone with two halogen-related modifications: a 9α-fluorine atom and an 11β-hydroxyl group. The fluorine modification is the source of the "fluoxy" prefix and is what distinguishes it from other 17α-methylated testosterone derivatives.
- Despite being one of the older FDA-approved AAS (continuously approved since 1957), fluoxymesterone has significant 17α-alkylation hepatotoxicity including documented cholestatic injury, peliosis hepatis, and hepatic tumor risk.
- The compound is distinctly more androgenic than anabolic: published anabolic-androgenic ratio of approximately 1900:850 (in animal assays). Most users do not see substantial muscle mass gains; effects are concentrated in strength, aggression, and tissue "hardening."
- No clinically significant aromatization to estrogen, though the compound is unusual in producing some estrogenic effects through alternative mechanisms (gynecomastia has been documented despite no aromatization, similar to oxymetholone; the mechanism is debated and may involve direct estrogen receptor activity).
- The compound has been used in clinical breast cancer treatment for decades, leveraging the anti-estrogenic effects of androgen administration on hormone-responsive tumors. Modern oncology has largely replaced fluoxymesterone with more effective alternatives (tamoxifen, aromatase inhibitors). PMID: 13675999
- Originally manufactured by Upjohn as Halotestin in the United States. The brand-name product is no longer manufactured by Pfizer (which acquired Upjohn through Pharmacia), but generic fluoxymesterone (Androxy) remains available.
Legal status
Legal status
Schedule III controlled substance in the United States (DEA). FDA-approved for hypogonadism, delayed puberty, and breast cancer indications. WADA-prohibited at all times in competitive sport.